Bruker Corporation $BRKR Shares Bought by Sculptor Capital LP

Sculptor Capital LP lifted its position in Bruker Corporation (NASDAQ:BRKR) by 9.0% during the first quarter, Holdings Channel reports. The institutional investor owned 3,270,000 shares of the medical research company’s stock after buying an additional 270,000 shares during the quarter. Bruker makes up approximately 1.2% of Sculptor Capital LP’s investment portfolio, making the stock its 15th largest position. Sculptor Capital LP’s holdings in Bruker were worth $118,112,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BRKR. Orbis Allan Gray Ltd grew its holdings in Bruker by 5.4% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock worth $702,256,000 after acquiring an additional 761,258 shares during the period. State Street Corp lifted its holdings in Bruker by 2.5% in the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after acquiring an additional 91,706 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Bruker by 2,963.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after purchasing an additional 2,289,269 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Bruker by 23.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock valued at $84,556,000 after purchasing an additional 448,440 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Price Performance

NASDAQ BRKR opened at $60.45 on Monday. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.54. The company has a market cap of $9.20 billion, a PE ratio of -251.88, a PEG ratio of 1.94 and a beta of 1.29. The stock’s 50-day moving average price is $56.32 and its two-hundred day moving average price is $46.29.

Bruker (NASDAQ:BRKR) last announced its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. The company had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period last year, the company posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Monday, June 22nd. Bruker’s dividend payout ratio is -83.33%.

Wall Street Analysts Forecast Growth

BRKR has been the topic of a number of research reports. Leerink Partners boosted their target price on shares of Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Barclays lifted their price target on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. UBS Group set a $60.00 price target on Bruker in a report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. increased their price objective on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $56.79.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.